Vericel Corporation Revenue 2011-2025 | VCEL

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Vericel Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
237 M	198 M	164 M	156 M	124 M	118 M	90.9 M	63.9 M	54.4 M	51.2 M	28.8 M	19 K	21 K	18 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
237 M	18 K	91.9 M

Quarterly Revenue Vericel Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
67.5 M	63.2 M	52.6 M	-	57.9 M	52.7 M	51.3 M	-	45.6 M	45.9 M	41 M	-	38.6 M	37 M	36.1 M	-	34.5 M	39.5 M	34.6 M	45.2 M	32.3 M	20 M	26.7 M	39.4 M	30.5 M	26.2 M	21.8 M	31.3 M	22.5 M	19 M	18 M	23.4 M	14.3 M	17 M	9.36 M	16.5 M	10.9 M	12.8 M	14.1 M	15.4 M	11.3 M	13.6 M	10.8 M	14.7 M	9.66 M	4.43 M	-	-	-	3 K	8 K	19 K	2 K	2 K	2 K	-	9 K	9 K	9 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
67.5 M	2 K	24.1 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	732 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	18.1 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	18.7 M	$ 3.26	-3.12 %	$ 252 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	60.3 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Kamada Ltd. KMDA	161 M	$ 7.03	0.14 %	$ 260 M	Israel
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	364 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Can-Fite BioPharma Ltd. CANF	853 K	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	109 K	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	54.1 B	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	167 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	3.81 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	78.6 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	75 K	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	66.4 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	5 K	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	912 K	$ 1.29	-3.01 %	$ 7.03 M	China
Baudax Bio BXRX	1.27 M	-	0.59 %	$ 63 K	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Catalyst Biosciences CBIO	113 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	99.6 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	2.08 B	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	201 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	41 K	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	1 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	149 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	9.68 B	$ 174.42	1.11 %	$ 25.4 B	USA
Celldex Therapeutics CLDX	7.02 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Deciphera Pharmaceuticals DCPH	163 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	463 M	$ 11.54	0.87 %	$ 746 M	USA